<DOC>
	<DOCNO>NCT00323414</DOCNO>
	<brief_summary>Non-alcoholic steatohepatitis ( NASH ) , severe form liver injury spectrum non-alcoholic fatty liver disease ( NAFLD ) , emerge major cause chronic liver disease develop country . Among adult United States , prevalence 5.7 % 17 % . These rate expect increase concurrent epidemic obesity type 2 diabetes mellitus , major risk factor NAFLD NASH . In addition high prevalence , NASH also progressive fibrotic disease advance cirrhosis liver relate death 20 % 12 % patient , respectively . Among NASH patient cirrhosis , 40 % liver relate death . Diabetics particularly prone experience poor outcome . No therapy proven effective patient NASH . The purpose study find whether treatment polyunsaturated fatty acid ( eicosapentaenoic acid [ EPA ] combine docosahexaenoic acid [ DHA ] call Opti-EPA ) improve NASH compare treatment placebo pill . The placebo pill contain corn oil contain capsule , medical effect body . The investigator determine improvement NASH microscopic change subject 's liver tissue 48 week treatment . This mean subject need liver biopsy treatment . Omega-3 fatty acid form polyunsaturated fat , one four basic type fat body get food . ( Cholesterol , saturate fat , monounsaturated fat others . ) One 's body make type fat ; come food source . These fat find food like cold water fish ( tuna , salmon , mackerel ) , vegetable product like flaxseed oil walnut . Research show polyunsaturated fat good people . Studies show good heart health play role keep blood cholesterol level low , keep irregular heart rhythm stable , reduce blood pressure . The drug study , Opti-EPA , nutritional supplement . They review Food Drug Administration ( FDA ) like medicine . Opti-EPA consider experimental study . This mean United States Food Drug Administration ( FDA ) approve use people nonalcoholic fatty liver disease .</brief_summary>
	<brief_title>Polyunsaturated Fatty Acids ( PUFA ) Treatment Non-Alcoholic Steatohepatitis ( NASH ) Patients With Type 2 Diabetes Mellitus ( PUFA )</brief_title>
	<detailed_description>Although proven effective treatment NASH , dietary supplementation long chain omega-3 polyunsaturated fatty acid ( PUFA 's ) may beneficial . This suggestion base three previously report observation : first , patient NASH consume less PUFAs saturate fat subject without NASH . Second , PUFAs beneficial patient hypertension hypertriglyceridemia . Third , PUFAs decrease lipid peroxidation ameliorate hepatic steatosis animal model NAFLD . We therefore hypothesize administration PUFAs , eicosapentaenoic acid ( EPA ) docosahexaenoic acid ( DHA ) reduce hepatic fat content , inflammation hepatic injury patient type 2 diabetes mellitus NASH . Aims To determine patient type 2 diabetes mellitus NASH dietary supplementation purify omega-3 fatty acid ( EPA DHA ) : 1 . Decrease histologic severity NASH . 2 . Alter expression gene important pathway hepatic lipid synthesis oxidation . Study design : Patients meet inclusion criterion randomize receive omega-3 fatty acid placebo . Stratified randomization do base NASH CRN pathology score 5 .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>Adult patient ( age &gt; 18 year ) Have type 2 diabetes mellitus good control blood sugar ( hemoglobin A1c [ HbA1c ] &lt; 7.5 % ) stable regimen antidiabetic agent 4 month . NASH establish liver biopsy do within 6 month prior inclusion study determine establish histologic criterion Cirrhosis liver End stage target organ damage diabetes mellitus : advanced renal failure ( serum creatinine &gt; 2.0 mg/dl ) without dialysis , severe neuropathy , advanced peripheral vascular disease . Any organ dysfunction anticipate life expectancy le 2 year Coexistent etiology liver disease Significant alcohol consumption , define 30 g per day men 20 g per day woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>PUFA</keyword>
	<keyword>NASH</keyword>
	<keyword>Fatty Liver</keyword>
	<keyword>Insulin resistance</keyword>
	<keyword>Metabolic syndrome</keyword>
	<keyword>Nonalcoholic fatty liver disease</keyword>
	<keyword>Nonalcoholic steatohepatitis</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
</DOC>